Skip to content

New treatments for treatment-resistant depression: esketamine controversies - a narrative review.

Maj Vinberg

Danish medical journal August 4, 2026 DOI: 10.61409/a02260078 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Narrative review Peer reviewed
Topics Depression Esketamine
Key findings Argues that timely access to new treatments for treatment-resistant depression in Denmark is hindered by regulatory complexity, economic constraints, and scientific debate over novel psychotropics such as esketamine, and advocates for evidence-based, faster implementation pathways to reduce the individual and societal burden of severe depression.

Abstract

This narrative review examines barriers to Danish patients' timely access to new treatments for treatment-resistant depression, focusing on controversies around esketamine. Delays arise from regulatory complexity, economic constraints and scientific debate over novel psychotropics. The review advocates evidence-based, faster implementation pathways for new treatments to alleviate the overall individual and societal burden from severe depression in Denmark.

Comparable studies

Other narrative reviews on esketamine for depression, most cited first.

Explore topics

By condition and practice